Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-14 Open-Label Extension Study in Fibromyalgia
NCT07637162Phase 3
Key facts
- Status
- Enrolling by invitation
- Start
- Apr 2026
- Primary completion
- May 2028
- Countries
- 1
- Sponsor
- Axsome Therapeutics, Inc.
- Drugs
- esreboxetine
- Conditions
- fibromyalgia (FM)
01
Overview
Phase 3, open-label, single-arm trial of esreboxetine in fibromyalgia (FM), sponsored by Axsome Therapeutics, Inc. Primary endpoint: Long-term Safety at 52 weeks. Started Apr 2026; status: enrolling by invitation.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
AXS-14 (esreboxetine)
Up to 52 weeks of open-label AXS-14.
03
Who it enrols
Eligible subjects must have previously participated in the AXS-14-FM-301 (FORWARD) study.
04
Endpoints
Primary
Long-term Safety
Beyond the preview
Go deeper on NCT07637162.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637162.